Demand for immunity products to be sustained long-term says SIRIO
Movement towards healthy lifestyles and preventative supplements the lasting behavioural change post COVID-19.
Worldwide demand for immunity products has accelerated in recent months due to coronavirus. This trend is likely to deliver a 'new norm' of higher growth, says SIRIO Europe (Ayanda) — the European headquarters of the SIRIO Group, a global nutraceutical contract development, innovation and manufacturing organization (CDiMO).
Europe has already seen a significant spike in the demand for immunity products across the main economies. Recent weekly data from Euromonitor show an increased purchasing of vitamin C and multivitamins by consumers, with unusual levels of stockouts present throughout Europe.
During lockdowns, production and supply chains have been fairly robust, but there have still been large stock shortages. This is surprising given that we are approaching summer, which is not traditionally a peak period for these products. Anticipating a surge, Dr Dominique Baum, Managing Director at SIRIO Europe (Ayanda), advised that the company has secured a "very large inventory of ingredients to ensure continuity of supply" for all its customers.
In addition, confinement regulations have left consumers with reduced exposure to sunlight which, in turn, has increased sales of nutraceuticals containing vitamin D or other ingredients that compensate for the lack of natural daylight.
Also proving popular among consumers are products that strengthen their respiratory and cardiovascular systems, with omega-3 fatty acids and antioxidants (that may protect against oxidative stress). The company suggests the long-term cumulative effect will be continued growth in health-boosting and immune-boosting supplements, adding a further driver to an already expanding nutraceuticals class.
“The lasting impact of the virus will see a further acceleration of an already popular product class and, in the next few years, we will likely see many new innovative immune formulations delivered via softgels and gummies. Consumers will be looking for new ways to potentially boost health and immunity with combination products, and we anticipate those products with multiple actives are likely to be increasingly popular. It’s a difficult time for society, but it could lead to further improvements with an increased consumer focus on wellbeing,” said Dr Baum.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance